Comparative Efficacy of Magnesium and Potassium Towards Cholesterol and Quality of Life in Patients With Type 2 Diabetes Mellitus: A Randomised Single-Blinded Controlled Clinical Trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

The present study was designed to compare the effect of magnesium, potassium and both (potassium and magnesium combined) on cholesterol levels and quality of life (QoL) among patients with T2DM.

Why It Was Studied

Previous studies exploring the relationship between dietary potassium and magnesium intake and the risk of type 2 diabetes mellitus (T2DM) have yielded inconsistent results.

Who Took Part

The study group was 290 patients.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

The sample size was 290 patients with T2DM, who were divided into four groups: Group I (T1) that received control/placebo; Group II (T2) and Group III (T3) received magnesium and potassium supplements, respectively; and Group IV (T4) received both magnesium and potassium supplements.

How the Study Was Run

In design terms this was a randomized, single-blind and placebo-controlled study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

In this single-blind Vitamin D, K2, Magnesium and Zinc study one party knew the assignments and the other did not.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

A randomised controlled trial (single blinded) was conducted at The University of Lahore and Lahore Medical Research Center (LMRC).

What Was Measured

Topics PubMed links to this paper include Cholesterol, Diabetes Mellitus, Type 2, Dietary Supplements, Magnesium, Potassium and Quality of Life.

The authors tagged it with the keywords type 2 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 290 patients.

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Endocrinology, diabetes & metabolism), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.